Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs. (December 2016) - Colclough, N.; Ballard, P.G.; Barton, P.; Chen, K.; Cross, D.A.E.; Finlay, M.R.V.; Han, L.; Janefeldt, A.; Johnström, P.; Ward, R.A.; Wrigley, G.L.; Yan, Y.; et al.